Hypera S.A (SA:HYPE3) — Market Cap & Net Worth
Market Cap & Net Worth: Hypera S.A (HYPE3)
Hypera S.A (SA:HYPE3) has a market capitalization of $3.23 Billion (R$16.46 Billion) as of September 16, 2026. Listed on the SA stock exchange, this Brazil-based company holds position #4700 globally and #51 in its home market, demonstrating a 0.95% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hypera S.A's stock price R$23.38 by its total outstanding shares 703995955 (704.00 Million). Also see Hypera S.A balance sheet assets for a full breakdown of the balance sheet.
Hypera S.A Market Cap History: 2015 to 2026
Hypera S.A's market capitalization history from 2015 to 2026. Data shows growth from $2.14 Billion to $3.23 Billion (6.38% CAGR). Also see Hypera S.A (HYPE3) cash conversion ratio for how efficiently the company converts equity into cash flow.
Index Memberships
Hypera S.A is a constituent of 5 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
BOVESPA Index
BVSP
|
$611.11 Billion | 0.53% | #35 of 80 |
|
Bovespa Brazil 50
IBX50
|
$514.96 Billion | 0.63% | #26 of 50 |
|
SAO PAULO SE IBX50 INDEX
IBXL
|
$494.74 Billion | 0.65% | #25 of 50 |
|
SAO PAULO SE IGCX INDEX
IGCX
|
$627.46 Billion | 0.51% | #36 of 155 |
|
IVBX IND
IVBX
|
$213.40 Billion | 1.51% | #20 of 45 |
Weight: Hypera S.A's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Hypera S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hypera S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check HYPE3 share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.42x
Hypera S.A's market cap is 0.42 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.72x
Hypera S.A's market cap is 2.72 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.62 Billion | $3.23 Billion | $1.18 Billion | 0.81x | 2.22x |
| 2017 | $3.87 Billion | $3.50 Billion | $964.94 Million | 1.10x | 4.01x |
| 2018 | $3.44 Billion | $3.72 Billion | $1.13 Billion | 0.92x | 3.04x |
| 2019 | $4.21 Billion | $3.29 Billion | $1.16 Billion | 1.28x | 3.61x |
| 2020 | $4.18 Billion | $4.09 Billion | $1.30 Billion | 1.02x | 3.23x |
| 2021 | $3.59 Billion | $5.94 Billion | $1.33 Billion | 0.60x | 2.70x |
| 2022 | $5.91 Billion | $7.55 Billion | $1.70 Billion | 0.78x | 3.49x |
| 2023 | $4.83 Billion | $7.91 Billion | $1.65 Billion | 0.61x | 2.93x |
| 2024 | $2.50 Billion | $7.44 Billion | $1.34 Billion | 0.34x | 1.86x |
| 2025 | $3.25 Billion | $7.70 Billion | $1.20 Billion | 0.42x | 2.72x |
Competitor Companies of HYPE3 by Market Capitalization
Companies near Hypera S.A in the global market cap rankings as of September 16, 2026. Review how tangible is Hypera S.A's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Hypera S.A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Hypera S.A Historical Marketcap From 2015 to 2026
Between 2015 and today, Hypera S.A's market cap moved from $2.14 Billion to $ 3.23 Billion, with a yearly change of 6.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | R$3.23 Billion | -0.76% |
| 2025 | R$3.25 Billion | +30.24% |
| 2024 | R$2.50 Billion | -48.22% |
| 2023 | R$4.83 Billion | -18.40% |
| 2022 | R$5.91 Billion | +64.77% |
| 2021 | R$3.59 Billion | -14.19% |
| 2020 | R$4.18 Billion | -0.57% |
| 2019 | R$4.21 Billion | +22.42% |
| 2018 | R$3.44 Billion | -11.12% |
| 2017 | R$3.87 Billion | +47.61% |
| 2016 | R$2.62 Billion | +22.53% |
| 2015 | R$2.14 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Hypera S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.23 Billion USD |
| MoneyControl | $3.23 Billion USD |
| MarketWatch | $3.23 Billion USD |
| marketcap.company | $3.23 Billion USD |
| Reuters | $3.23 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hypera S.A
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Co… Read more